Hinge Health (NYSE:HNGE) Major Shareholder Insight Holdings Group, Llc Sells 112,477 Shares of Stock

Hinge Health Inc. (NYSE:HNGE) major shareholder Insight Holdings Group, Llc sold 112,477 shares of the business’s stock in a transaction on Tuesday, June 23rd. The shares were sold at an average price of $70.21, for a total transaction of $7,897,010.17. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Major shareholders that own 10% or more of a company’s stock are required to disclose their sales and purchases with the SEC.

Insight Holdings Group, Llc also recently made the following trade(s):

• On Wednesday, June 24th, Insight Holdings Group, Llc sold 390,917 shares of Hinge Health stock. The stock was sold at an average price of $71.15, for a total transaction of $27,813,744.55.
• On Monday, June 22nd, Insight Holdings Group, Llc sold 224,399 shares of Hinge Health stock. The stock was sold at an average price of $70.95, for a total transaction of $15,921,109.05.
• On Tuesday, June 16th, Insight Holdings Group, Llc sold 65,581 shares of Hinge Health stock. The shares were sold at an average price of $70.36, for a total transaction of $4,614,279.16.

Hinge Health Trading Down 0.0%

Shares of Hinge Health stock opened at $70.36 on Thursday. The stock has a market capitalization of $5.44 billion and a price-to-earnings ratio of -5.70. Hinge Health Inc. has a 1-year low of $30.08 and a 1-year high of $72.39. The firm’s 50-day moving average price is $55.45 and its two-hundred day moving average price is $47.16.

Hinge Health (NYSE:HNGE) last posted its earnings results on Tuesday, May 5th. The company reported $0.45 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.12 by $0.33. The company had revenue of $182.31 million during the quarter. Hinge Health had a negative net margin of 78.95% and a negative return on equity of 310.62%. The business’s revenue was up 47.2% on a year-over-year basis. During the same quarter last year, the firm posted $1.30 EPS. As a group, equities research analysts predict that Hinge Health Inc. will post 1.33 EPS for the current year.

Key Stories Impacting Hinge Health

Here are the key news stories impacting Hinge Health this week:

• Positive Sentiment: Hinge Health raised its Q2 2026 revenue guidance to $200 million-$202 million, above the Street’s $195 million estimate, and lifted full-year 2026 revenue guidance to $818 million-$824 million versus consensus of $801.6 million, signaling stronger growth expectations.
• Positive Sentiment: The stock continues to benefit from strong prior operating results, including revenue growth of 47.2% in the most recent reported quarter and earnings that beat analyst estimates, which supports the bullish analyst backdrop.
• Neutral Sentiment: Several analysts remain constructive on Hinge Health, with recent price targets in the $79-$90 range and a consensus rating of “Moderate Buy,” suggesting Wall Street still sees upside from current levels.
• Negative Sentiment: Major shareholder Insight Holdings Group sold a large block of shares in multiple June transactions, including 390,917 shares on June 24, 224,399 shares on June 22, and 112,477 shares on June 23, which can weigh on sentiment even though the sales were made under a pre-arranged 10b5-1 plan.
• Negative Sentiment: President James Pursley also sold 33,000 shares on June 22, adding to the cluster of insider selling that may raise concern about valuation after the stock’s recent run-up.

Wall Street Analysts Forecast Growth

HNGE has been the topic of several research analyst reports. KeyCorp increased their target price on Hinge Health from $75.00 to $90.00 and gave the stock an “overweight” rating in a report on Friday, June 12th. Zacks Research raised Hinge Health from a “hold” rating to a “strong-buy” rating in a report on Wednesday, May 13th. Raymond James Financial increased their price objective on shares of Hinge Health from $70.00 to $80.00 and gave the stock an “outperform” rating in a report on Monday, June 15th. Evercore restated an “outperform” rating and issued a $45.00 price objective on shares of Hinge Health in a research report on Wednesday, April 8th. Finally, Robert W. Baird boosted their target price on shares of Hinge Health from $55.00 to $65.00 and gave the stock a “neutral” rating in a research note on Wednesday, June 17th. Two investment analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $75.80.

Institutional Investors Weigh In On Hinge Health

A number of institutional investors and hedge funds have recently made changes to their positions in the company. Marshall Wace LLP bought a new position in Hinge Health in the second quarter valued at about $367,000. Sei Investments Co. bought a new position in shares of Hinge Health in the 2nd quarter valued at about $869,000. Squarepoint Ops LLC bought a new position in shares of Hinge Health in the 2nd quarter valued at about $19,706,000. Raymond James Financial Inc. acquired a new stake in shares of Hinge Health during the 2nd quarter worth approximately $3,258,000. Finally, Sandia Investment Management LP bought a new stake in shares of Hinge Health during the second quarter worth approximately $657,000.

About Hinge Health

Hinge Health (NYSE: HNGE) is a digital musculoskeletal (MSK) clinic that provides end-to-end solutions for the prevention and management of musculoskeletal conditions. The company’s platform combines wearable motion sensors, personalized exercise therapy guided by licensed physical therapists, and behavioral health coaching to deliver tailored treatment plans. By integrating technology with evidence-based clinical protocols, Hinge Health aims to reduce pain, improve mobility and decrease reliance on more invasive interventions such as surgery or opioid prescriptions.

Founded in 2015 and headquartered in San Francisco, Hinge Health partners with employers, health plans and other payers to offer its self-directed, app-based programs.